Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
| Status: | Terminated |
|---|---|
| Conditions: | Breast Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/22/2017 |
| Start Date: | July 23, 2007 |
| End Date: | March 20, 2017 |
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Subjects with advanced or metastatic (spread to other parts of the body) breast cancer that
is HER2/neu-positive will take part in this study. This type of breast cancer has a high
amount of a protein called HER2. HER2 is part of a family of receptors found on both cancer
and normal cells. This family of receptors is important for cell growth and is found in many
tumor types. The purpose of this research study is to compare an approved treatment for
breast cancer capecitabine, also called Xeloda®, to the combination of capecitabine plus an
experimental drug, lapatinib also known as Tykerb®, for treatment of advanced or metastatic
breast cancer that is HER2/neu-positive.Capecitabine is an approved type of chemotherapy
used to treat certain cancers including breast cancer. Capecitabine fights cancer by
interfering with the ability of cells to divide and tumor growth. Lapatinib (Tykerb®) is
considered "investigational", which means the drug has not been approved by the US Food and
Drug Administration (FDA) for sale as a prescription or over-the-counter medication.
Lapatinib may slow or stop cancer cells from growing by inhibiting the growth of cancer
cells. However, this theory has not been proven. The addition of the study drug (lapatinib)
to capecitabine may help stop cancer cells as well as or better than capecitabine alone.
Other studies have demonstrated activity and tolerability of lapatinib either alone or in
combination with capecitabine in the treatment of breast cancer.Subjects will receive
capecitabine and lapatinib. A treatment period will be 21 days long. This period is known as
a "cycle". All medications will be given by mouth. Subjects will take capecitabine for 2
weeks straight (Day 1-14) followed by a 1 week without capecitabine (Day 15-21). Doses of
lapatinib will be taken daily continuously for 21 days (Day 1-Day 21) which means that
subjects will still take lapatinib on the week that they do not take capecitabine (Day
15-21). Subjects will continue to receive these medications unless they experience severe,
serious and/or excessive side effects, the cancer becomes worse, the subjects wishes to no
longer participate or the study doctor feels it is not in the best interest to continue
treatment.Tests and procedures such as physical exam, blood tests, CT or MRI, ECG, ECHO
and/or MUGA tests will be conducted at one or more of the following time points: before the
study starts, before each cycle, every 6 and 12 weeks, and after the last dose of
capecitabine/lapatinib treatment.
is HER2/neu-positive will take part in this study. This type of breast cancer has a high
amount of a protein called HER2. HER2 is part of a family of receptors found on both cancer
and normal cells. This family of receptors is important for cell growth and is found in many
tumor types. The purpose of this research study is to compare an approved treatment for
breast cancer capecitabine, also called Xeloda®, to the combination of capecitabine plus an
experimental drug, lapatinib also known as Tykerb®, for treatment of advanced or metastatic
breast cancer that is HER2/neu-positive.Capecitabine is an approved type of chemotherapy
used to treat certain cancers including breast cancer. Capecitabine fights cancer by
interfering with the ability of cells to divide and tumor growth. Lapatinib (Tykerb®) is
considered "investigational", which means the drug has not been approved by the US Food and
Drug Administration (FDA) for sale as a prescription or over-the-counter medication.
Lapatinib may slow or stop cancer cells from growing by inhibiting the growth of cancer
cells. However, this theory has not been proven. The addition of the study drug (lapatinib)
to capecitabine may help stop cancer cells as well as or better than capecitabine alone.
Other studies have demonstrated activity and tolerability of lapatinib either alone or in
combination with capecitabine in the treatment of breast cancer.Subjects will receive
capecitabine and lapatinib. A treatment period will be 21 days long. This period is known as
a "cycle". All medications will be given by mouth. Subjects will take capecitabine for 2
weeks straight (Day 1-14) followed by a 1 week without capecitabine (Day 15-21). Doses of
lapatinib will be taken daily continuously for 21 days (Day 1-Day 21) which means that
subjects will still take lapatinib on the week that they do not take capecitabine (Day
15-21). Subjects will continue to receive these medications unless they experience severe,
serious and/or excessive side effects, the cancer becomes worse, the subjects wishes to no
longer participate or the study doctor feels it is not in the best interest to continue
treatment.Tests and procedures such as physical exam, blood tests, CT or MRI, ECG, ECHO
and/or MUGA tests will be conducted at one or more of the following time points: before the
study starts, before each cycle, every 6 and 12 weeks, and after the last dose of
capecitabine/lapatinib treatment.
Inclusion Criteria:
- Histologically confirmed invasive breast cancer
- Stage IIIB, IIIC with T4 lesion or Stage IV disease
- Breast cancer must be determined to be HER2-positive. Assays using fluorescence in
situ hybridization (FISH) require gene amplification and assays using
immunohistochemistry require a strongly positive (3+) staining intensity score in
primary or metastatic tumor tissue
- Measurable disease according to RECIST (Response Evaluation Criteria In Solid Tumors)
- Age ³ 18 years of age
- ECOG performance status 0, 1 or 2 (Appendix B)
- Life expectancy of 3 months or longer
- Able to swallow oral medication
- Adequate end organ function
- Left ventricular ejection fraction
- Women of childbearing potential and men must agree to use adequate contraception
prior to study entry and for the duration of study participation
- Written informed consent
Exclusion Criteria:
- Prior treatment with chemotherapy for advanced or metastatic breast cancer
- Prior anti-ErbB1 and/or ErbB2 inhibitor therapy for breast cancer; neoadjuvant or
adjuvant treatment with trastuzumab will be allowed provided the last dose was > 6
months prior to enrollment in study
- Symptomatic or untreated brain metastases or carcinomatous meningitis
- Uncontrolled illnesses including symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia requiring therapy, myocardial infarction within
the past 6 months, or active infection
- History of other primary malignancies in the last 5 years prior to on-study date
except carcinoma in situ of the cervix and nonmelanoma skin cancer
- History of allergic reaction attributed to compounds of similar chemical or biologic
composition to capecitabine and/or lapatinib
- Concurrent treatment with other investigational or commercial anti-cancer agent(s)
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Less than 3 weeks since prior radiotherapy
- Less than 2 weeks since prior hormonal therapy
- Known HIV-positive patients receiving combination anti-retroviral therapy are
excluded from the study because of possible pharmacokinetic interactions with
lapatinib
- Pregnant or lactating women at anytime during the study
- Patients with GI tract disease resulting in an inability to take oral medication,
malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures
affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative
colitis)
- Certain medications that act through the CYP450 system are specifically prohibited in
patients receiving lapatinib because in vitro data indicate that the agents has the
potential to interact with cytochrome P450 enzymes CYP3A4. Certain other agents
should be used with caution. Medications that are specifically prohibited can be
found in Appendix C.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials